WHO Prequalification of Diagnostics
Generated by GPT-5-miniExpansion Funnel Raw 76 → Dedup 0 → NER 0 → Enqueued 0
| WHO Prequalification of Diagnostics | |
|---|---|
| Name | WHO Prequalification of Diagnostics |
| Formation | 2007 |
| Type | Program |
| Headquarters | Geneva, Switzerland |
| Parent organization | World Health Organization |
WHO Prequalification of Diagnostics
The WHO Prequalification of Diagnostics program is a global initiative administered by the World Health Organization in Geneva that evaluates in vitro diagnostics for procurement by United Nations agencies and Global Fund partners. It supports procurement decisions across programs such as UNICEF, UNDP, UNAIDS, Gavi, the Vaccine Alliance, and Global Fund to Fight AIDS, Tuberculosis and Malaria by assessing performance, quality, and manufacturing standards. The program interacts with national regulatory authorities including the European Medicines Agency, the US Food and Drug Administration, and the Medicines and Healthcare products Regulatory Agency to harmonize requirements and accelerate access to diagnostics.
Overview
The program was established to ensure availability of reliable diagnostics for priority diseases like HIV/AIDS, malaria, hepatitis B, hepatitis C, and tuberculosis by prequalifying tests that meet international standards used by World Bank-funded and UN procurement mechanisms. It operates alongside initiatives such as the Global Diagnostics Initiative, Foundation for Innovative New Diagnostics, and the PATH (organization) diagnostics portfolio to support scale-up in low- and middle-income countries including India, Kenya, South Africa, and Brazil. The prequalification pathway evaluates dossiers, site inspections, and performance data from clinical studies conducted in settings represented by Democratic Republic of the Congo, Mozambique, and Uganda.
Scope and eligibility
Eligibility covers in vitro diagnostics for priority conditions identified by WHO technical programs, including assays for SARS-CoV-2, Zika virus, Ebola virus disease, and neglected tropical diseases addressed by Medicines for Malaria Venture. Manufacturers from jurisdictions such as China, Germany, Japan, and United States may apply provided they submit documentation consistent with standards from the International Organization for Standardization and comply with Good Manufacturing Practice norms aligned with the World Trade Organization frameworks. Products previously assessed by stringent regulatory authorities like the Swissmedic and the Health Canada may be eligible for an accelerated review in coordination with regional regulators including the African Union and the European Commission.
Application and assessment process
Applicants submit technical dossiers that include analytical validation, clinical performance, and quality management system attestations, following templates similar to those used by the European Directorate for the Quality of Medicines and the U.S. Centers for Disease Control and Prevention. The assessment includes document review, laboratory evaluation at WHO-designated reference laboratories such as the Institut Pasteur, London School of Hygiene & Tropical Medicine, and the National Institutes of Health, and on-site inspections modeled on audit practices from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Advisory committees composed of experts from institutions like Johns Hopkins Bloomberg School of Public Health, Harvard T.H. Chan School of Public Health, and the London School of Economics provide scientific oversight.
Performance evaluation and quality assurance
Performance evaluation requires demonstration of sensitivity, specificity, and robustness in field-representative studies often conducted in partnership with academic centers such as Makerere University, University of Cape Town, and Massachusetts Institute of Technology. Quality assurance mechanisms include batch testing, stability studies, and verification of supply chain integrity with standards referenced from the International Electrotechnical Commission, the Pan American Health Organization, and the European Centre for Disease Prevention and Control. The program issues performance summaries that inform procurement by entities such as Doctors Without Borders, Clinton Health Access Initiative, and Save the Children.
Post-market surveillance and re-evaluation
Post-market surveillance leverages adverse event reporting systems coordinated with national agencies like the South African Health Products Regulatory Authority, the India Central Drugs Standard Control Organization, and networked pharmacovigilance platforms supported by WHO Collaborating Centres. Re-evaluation may be triggered by changes in manufacturing sites, emergence of new variants as seen in SARS-CoV-2 outbreaks, or data from implementation studies in Peru and Bangladesh. The program collaborates with procurement partners including UNICEF Supply Division and Pan American Health Organization to withdraw or suspend listings when quality or performance is compromised.
Impact and uptake in global health programs
Prequalified diagnostics have been used at scale in vaccination campaigns coordinated by Gavi, the Vaccine Alliance and case-finding initiatives funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria and bilateral donors such as the United States Agency for International Development and the Department for International Development. Adoption by national programs in countries like Rwanda, Ethiopia, and Cambodia has supported disease surveillance networks linked to the Global Outbreak Alert and Response Network and integrated laboratory networks supported by African Centres for Disease Control and Prevention. Economic analyses by institutions such as the World Bank and Bill & Melinda Gates Foundation illustrate cost-effectiveness in pooled procurement arrangements.
Governance and regulatory context
Governance is provided by the World Health Organization secretariat with technical guidance from expert advisory groups and alignment with standards developed by the International Medical Device Regulators Forum, the World Trade Organization agreements, and regional regulatory harmonization efforts like the African Medicines Regulatory Harmonization initiative. The program interfaces with treaty frameworks such as the International Health Regulations (2005) and collaborates with multilateral stakeholders including UNICEF, UNAIDS, and the Global Fund to ensure diagnostics meet public health needs while respecting national regulatory sovereignty.